The ‘Pulmonary Fibrosis Australasian Clinical Trials’ or PACT network is a component of the CRE-PF supporting PF clinical trials in Australasia . It is led by Prof Dan Chambers.
The vision of PACT is to reduce the morbidity and mortality associated with pulmonary fibrosis and improve the quality of life for people living with pulmonary fibrosis, their carers and families in Australasia through the facilitation and coordination of high quality clinical research. PACT supports randomised, controlled clinical trials to evaluate existing or new medications, combinations of medications, and defined management strategies for patients with PF.
The specific objectives of PACT are to:
- Support investigator-driven pulmonary fibrosis research through: peer review, facilitating collaboration; streamlining HREC/governance approval processes.
- Engage with consumers to improve access to current information and increase awareness about pulmonary fibrosis clinical research in Australasia.
- Support pharma-sponsored pulmonary fibrosis research though: advocating for pulmonary fibrosis research to be conducted in Australasia; assisting sponsors/CROs in identifying suitable sites
- Advocate for, and actively disseminate research outcomes/translate research into practice.
Prof Dan Chambers talks about the collaborative PACT team of the CRE-PF, leading PF specialists, Lung Foundation Australia and consumers here.
For further information about PACT, please visit the PACT website.